Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Esomeprazole is a proton pump inhibitor used to treat GERD, reduce the risk of NSAID associated gastric ulcers, eradicate H. pylori, and to treat conditions causing gastric acid hypersecretion. Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage...
- Mechanism
- Curator reviewed
Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect that persists longer than 24 hours.
- Primary indication
- Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use,...Curator reviewed · 17 structured indications
- Formula / weight
- C17H19N3O3S · 345.416 g/mol (avg)
- First approval
- Canada, 2001 · United States, 2001 · European Union, 2016
- Also known as
- (S)-omeprazole · Perprazole
- Code names
- A02BC05 · D961H · H 199/18
- Brand names
- Nexium
- Riopan
- Vimovo
Resolves to
SUBDBMMJDZJVOS-DEOSSOPVSA-NSMILESCOC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1What you can answer from here — as of September 21, 2026
Which drugs share a target with Esomeprazole, and which of those have an active Phase 3 trial?